James J. Ferguson III - 05 Feb 2025 Form 4 Insider Report for Cadrenal Therapeutics, Inc. (CVKD)

Role
Chief Medical Officer
Signature
/s/ Matthew K. Szot, Attorney-in-fact
Issuer symbol
CVKD
Transactions as of
05 Feb 2025
Net transactions value
$0
Form type
4
Filing time
06 Feb 2025, 16:51:35 UTC
Previous filing
15 Dec 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CVKD Stock Options Award $0 +60,000 $0.000000 60,000 05 Feb 2025 Common Stock 60,000 $19.75 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of options to purchase 60,000 shares of common stock, which shall vest 1/4 on March 1, 2026 and thereafter pro rata on a monthly basis over three years, subject to the Reporting Person's continued service to the Issuer through each vesting date, having an exercise price equal to the fair market value of the Issuer's common stock on the effective date of the grant.